InsidersTradesSigma
Track the Natera, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Natera, Inc. has recorded 947 public disclosures. Market capitalisation: €48.8bn. The latest transaction was disclosed on 28 August 2026 (Attribution). Among the most active insiders: Sheena Jonathan. The full history is free.
Natera, Inc. has reported a total of 155 insider trading declarations in the past 90 days, with a total selling amount of approximately 82 million euros and no reported buying activity. The top insiders include Roelof Botha, who made 8 declarations totaling about 14.8 million euros, Jonathan Sheena with 31 declarations totaling approximately 13.2 million euros, and Daniel Rabinowitz, who made 5 declarations totaling around 11.5 million euros. Significant recent sales include Steven L. Chapman, who sold approximately 7.8 million euros worth of shares on June 4, 2026, and Daniel Rabinowitz, who sold about 6.9 million euros on June 24, 2026. Other notable sales include Sheena Jonathan's sale of around 5.2 million euros on August 7, 2026, and multiple sales by Roelof Botha on June 3, 2026, totaling over 7 million euros.
Auto-generated summary, refreshed daily.Updated 1d ago
947
Insider Decl.
n/a
Thresholds
€2m
3 ops.
Buy Volume
€205m
389 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Natera, Inc. Strong Buy (bullish), based on 21 analysts. Average price target: US$336.74.
45Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,149 of 29,024 companies
36.3
score / 100
Value35
Quality38
FCF yld0.2%
Earn yld-0.4%
EV/EBITDA·
ROE-13%
Gross mgn65%
Net mgn-9.0%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 28 August 2026
Declarations947 total
20,000 shares0Common StockSEC:0002010135-26-000020:0
6,517 shares@ US$321.53Common StockSEC:0002010135-26-000020:1
6,000 shares@ US$325.32370.0043% mcap6.1% of flowCommon StockSEC:0001646649-26-000030:0
18,000 shares@ US$330.61670.016% mcap19.8% of flowCommonSEC144:0001949846-26-000478
2,000 shares@ US$320.900.0017% mcap69.5% of flowCommonSEC144:0001950047-26-007836
2,000 shares@ US$320.900.0017% mcap1.8% of flowCommon StockSEC:0001646382-26-000018:0
400 shares@ US$310.2250.0003% mcap0.5% of flowCommon StockSEC:0001646649-26-000029:1
900 shares@ US$313.06720.0007% mcap1.2% of flowCommon StockSEC:0001646649-26-000029:3
850 shares@ US$314.25170.0007% mcap1.1% of flowCommon StockSEC:0001646649-26-000029:4
600 shares@ US$315.31750.0005% mcap0.8% of flowCommon StockSEC:0001646649-26-000029:5
5,111 shares@ US$316.61180.0043% mcap6.7% of flowCommon StockSEC:0001646649-26-000029:6
200 shares@ US$317.9650.0002% mcap0.3% of flowCommon StockSEC:0001646649-26-000029:7
100 shares@ US$318.630.0001% mcap0.1% of flowCommon StockSEC:0001646649-26-000029:8
489 shares@ US$320.900.0004% mcap0.7% of flowCommon StockSEC:0001646649-26-000029:9
400 shares@ US$311.87880.0003% mcap0.5% of flowCommon StockSEC:0001646649-26-000029:2
100 shares@ US$308.400.0001% mcap0.1% of flowCommon StockSEC:0001646649-26-000029:0
1,182 shares@ US$267.98930.0008% mcap0.6% of flowCommon StockSEC:0001711968-26-000021:0
128 shares@ US$268.69640.0001% mcap0.2% of flowCommon StockSEC:0002010019-26-000024:6
296 shares@ US$267.08380.0002% mcap0.2% of flowCommon StockSEC:0001711968-26-000021:5
295 shares@ US$267.98930.0002% mcap0.7% of flowCommon StockSEC:0002010135-26-000019:0
612 shares@ US$268.21870.0004% mcap0.3% of flowCommon StockSEC:0001711968-26-000021:6
410 shares@ US$267.98930.0003% mcap0.5% of flowCommon StockSEC:0002010019-26-000024:0
192 shares@ US$265.2750.0001% mcap0.2% of flowCommon StockSEC:0002010019-26-000024:4
676 shares@ US$263.86220.0005% mcap0.3% of flowCommon StockSEC:0001711968-26-000021:3
200 shares@ US$261.48750.0001% mcap0.3% of flowCommon StockSEC:0002010019-26-000024:2
25 of 947 declarations
About Natera, Inc.
Natera, Inc. is a U.S.-based molecular diagnostics company listed on the NASDAQ under the ticker NTRA, in the United States. For international investors, the company is best understood as a precision-medicine leader built around cell-free DNA (cfDNA) testing, with a founding story that dates back to 2004 and a long-term mission to change standards of care in genetic disease. Its operational center is in Austin, Texas, while it also runs laboratories in San Carlos, California. Natera combines molecular biology, bioinformatics, and increasingly AI-enabled analytics to detect and interpret genetic signals from a blood sample. The business is organized around three major areas. In women’s health, Panorama is the company’s flagship non-invasive prenatal test, used to screen for common chromosomal conditions in pregnancy. In oncology, Signatera is the core growth and strategic platform: a tumor-informed minimal residual disease (MRD) assay used for cancer recurrence monitoring, treatment response assessment, and longitudinal disease management. In organ health, Prospera supports transplant rejection surveillance, while Renasight addresses genetic causes of chronic kidney disease. This portfolio gives Natera exposure to multiple high-value clinical workflows rather than a single diagnostic niche. From a competitive standpoint, Natera positions itself as one of the leading cfDNA diagnostics companies, with differentiation based on assay design, clinical evidence, and an extensive publication record. The company highlights the strength of its validation studies, broad clinical utility, and the depth of its data assets. That said, the commercial footprint is still overwhelmingly U.S.-centric: international revenue remains relatively small, so reimbursement trends, physician adoption, and payer coverage in the United States are especially important to the investment case. Recent developments underscore the company’s momentum. On May 7, 2026, Natera reported first-quarter 2026 revenue of $696.6 million, up 38.8% year over year, supported by continued test volume growth, including strong oncology growth. During 2025 and early 2026, the company acquired Foresight Diagnostics, launched proprietary AI foundation models to speed diagnostic and therapeutic innovation, and secured an FDA approval for Signatera CDx in muscle-invasive bladder cancer. Natera therefore offers investors a growth-oriented healthcare diagnostics story with meaningful clinical optionality, but also with execution risk, heavy R&D intensity, and continued dependence on U.S. market adoption.
